Accelerating Development of Non-Opioid Pain Medicines – American Pain Society’s Conference on Analgesic Trials (APS-CAT)
Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Research will chair the 4th annual American Pain Society Conference on Analgesic Trials on Wednesday, April 3, 2019 in Milwaukee, Wisconsin. The Conference theme is “Accelerating Development of Non-Opioid Pain Medicines.”
PASADENA, CA – March 8, 2019
The theme of this year’s APS-CAT is Accelerating Development of Non-Opioid Pain Medicines. APS-CAT is a forum for experts from industry, academia and regulatory bodies to discuss new ideas and best practices in the design and conduct of clinical pain trials, via speaker presentations and open Q & A. This year’s agenda is below:
- Nathaniel Katz, M, CEO, Analgesic Solutions
- A Scientific Approach to Training for Reduction of Measurement Error in Clinical Trials
- Robert Dworkin, PhD, Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, University of Rochester Director, ACTTION public-private partnership with the FDA
- “The Greatest Teacher, Failure Is:” False Positive and False Negative Results in Analgesic Clinical Trials
- William Schmidt, PhD, President, NorthStar Consulting
- Nested Clinical Trial Design: A Faster Pathway for Analgesic Development Programs
- Michael Oshinsky, MD, Program Director, Pain and Migraine, National Institute of Neurological Disorders and Stroke, National Institutes of Health
- Securing an NIH Grant: What NIH Looks for in an Application, and How to Tailor Your Program for a Successful Relationship with NIH
- Lee Simon, MD, Principal, SDG, LLC & Former Director, FDA Division of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products
- An Analysis of FDA’s New Framework for Real-World Evidence Program
- Neil Singla, MD, CEO, Lotus Clinical Research
- Acute vs. Chronic Pain: Experimental Models, Regulatory Pathways and Market Opportunities
- Industry Leader Perspectives on Scientific, Regulatory and Economic Concerns for Rapid Development of Non-Opioid Analgesics:
- Barry Quart, Pharm. D. – CEO, Heron Therapeutics
- Scott Kelley, MD – CMO, Flexion Therapeutics
- James Campbell, MD – President and CSO, Centrexion Therapeutics
Registration is $150 and includes lunch.
Register today at http://americanpainsociety.org/meetings-and-events/2019-scientific-meeting/conference-on-analgesic-trials
Contact:
Hadley Rakowski
Lotus Clinical Research
802-343-5470
hrakowski@lotuscr.com
www.lotuscr.com
https://www.newswire.com/news/accelerating-development-of-non-opioid-pain-medicines-american-pain-20834732
